CA
ALXN

Cullinan Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Cullinan Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21,805
Closed -$4.01M – 242
2021
Q2 		$4.01M Sell
21,805
-4,862
-18% -$835K 0.22% 100
2021
Q1 		$4.08M Sell
26,667
-22,065
-45% -$3.41M 0.23% 100
2020
Q4 		$7.61M Sell
48,732
-947
-2% -$122K 0.46% 63
2020
Q3 		$5.68M Buy
49,679
+32,625
+191% +$3.52M 0.37% 74
2020
Q2 		$1.91M Buy
+17,054
New +$1.81M 0.13% 111

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Cullinan Associates's ALXN Position: Q3 2021 in Review

Cullinan Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 21,805 shares — an estimated $4.01M sold.

Cullinan Associates first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $7.61M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Cullinan Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cullinan Associates sold 21,805 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.01M.
  • Cullinan Associates first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Cullinan Associates's Alexion Pharmaceuticals position peaked at $7.61M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Cullinan Associates's 13F filing for Q3 2021, filed 8 Oct 2021.